Recomendaciones sobre el uso de metotrexato en pacientes con artritis psoriásica

Nestle, 2009, Psoriasis, N Engl J Med, 361, 496, 10.1056/NEJMra0804595 Gladman, 2005, Psoriatic arthritis: Epidemiology, clinical features, course, and outcome, Ann Rheum Dis, 64, ii14 Torre Alonso, 1991, Psoriatic arthritis (PA): A clinical, immunological and radiological study of 180 patients, Br J Rheumatol, 30, 245, 10.1093/rheumatology/30.4.245 Gladman, 2011, Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?, Ann Rheum Dis, 70, 2152, 10.1136/ard.2011.150938 Zweegers, 2016, Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review, Acta Derm Venereol, 96, 453, 10.2340/00015555-2276 Ramiro, 2016, Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis, Ann Rheum Dis, 75, 490, 10.1136/annrheumdis-2015-208466 Gossec, 2016, European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis, 75, 499, 10.1136/annrheumdis-2015-208337 Ritchlin, 2009, Treatment recommendations for psoriatic arthritis, Ann Rheum Dis, 68, 1387, 10.1136/ard.2008.094946 Silva-Fernandez, 2015, Semin Arthritis Rheum, 44, 633, 10.1016/j.semarthrit.2014.11.005 Tornero Molina, 2017, Recommendations for the use of parenteral methotrexate in rheumatic diseases, Reumatol Clin Tornero Molina, 2015, Recommendations for the use of methotrexate in rheumatoid arthritis: Up and down scaling of the dose and administration routes, Reumatol Clin, 11, 3, 10.1016/j.reuma.2014.02.012 Yelamos, 2015, Systemic methotrexate for the treatment of psoriasis, Expert Rev Clin Immunol, 11, 553, 10.1586/1744666X.2015.1026894 Antoni, 2005, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), Arthritis Rheum, 1227, 36 Antoni, 2005, Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial, Ann Rheum Dis, 64, 1150, 10.1136/ard.2004.032268 Baranauskaite, 2012, Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study, Ann Rheum Dis, 71, 541, 10.1136/ard.2011.152223 Asaduzzaman, 2014, Efficacy and safety of leflunomide in psoriatic arthritis, J Pakistan Assoc Dermatol, 24, 51 Willkens, 1984, Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis, Arthritis Rheum, 27, 376, 10.1002/art.1780270403 Kingsley, 2012, A randomized placebo-controlled trial of methotrexate in psoriatic arthritis, Rheumatology (Oxford, England), 51, 1368, 10.1093/rheumatology/kes001 Black, 1964, Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients, JAMA, 189, 743, 10.1001/jama.1964.03070100037007 Chandran, 2008, Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort, J Rheumatol, 35, 469 Chandran, 2010, Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis, J Rheumatol, 37, 1508, 10.3899/jrheum.091311 Coates, 2016, Methotrexate efficacy in the tight control in psoriatic arthritis Study, J Rheumatol, 43, 356, 10.3899/jrheum.150614 Espinoza, 1992, Psoriatic arthritis: Clinical response and side effects to methotrexate therapy, J Rheumatol, 19, 872 Heiberg, 2007, The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study, Ann Rheum Dis, 66, 1038, 10.1136/ard.2006.064808 Kragballe, 1983, Methotrexate in psoriatic arthritis: A retrospective study, Acta Derm Venereol, 63, 165 Sheane, 2016, Attainment of minimal disease activity using methotrexate in psoriatic arthritis, J Rheumatol, 43, 1718, 10.3899/jrheum.160111 Spadaro, 1995, Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study, Clin Exp Rheumatol, 13, 589 Zachariae, 1987, Methotrexate treatment of psoriatic arthritis, Acta Derm Venereol, 67, 270 Kavanaugh, 2014, Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study), Ann Rheum Dis, 73, 1689, 10.1136/annrheumdis-2013-204902 Fagerli, 2014, The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: Results from 440 patients included in the NOR-DMARD study, Ann Rheum Dis, 73, 132, 10.1136/annrheumdis-2012-202347 Eder, 2014, Tumour necrosis factor alpha blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis, Ann Rheum Dis, 73, 1007, 10.1136/annrheumdis-2012-202959 Belzunegui, 2001, Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate, Clin Exp Rheumatol, 19, 727 Calasan, 2013, Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis, Arthritis Res Ther, 15, R217, 10.1186/ar4413 Glintborg, 2014, Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: Results from the nationwide registries DANBIO and ICEBIO, Rheumatology (Oxford England), 53, 2100, 10.1093/rheumatology/keu252 Haque, 2016, Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: A cross-sectional study, J Rheumatol, 43, 376, 10.3899/jrheum.141359 Lacaille, 2000, Longterm therapy of psoriatic arthritis: Intramuscular gold or methotrexate?, J Rheumatol, 27, 1922 Kavanaugh, 2007, Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial, Ann Rheum Dis, 66, 498, 10.1136/ard.2006.058339 Kavanaugh, 2009, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study, Arthritis Rheum, 60, 976, 10.1002/art.24403 Mease, 2006, Alefacept in psoriatic arthritis study G. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study, Arthritis Rheum, 54, 1638, 10.1002/art.21870 Coates, 2015, Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial, Lancet, 386, 2489, 10.1016/S0140-6736(15)00347-5 Schiff, 2017, Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis, Rheumatol Int, 37, 213, 10.1007/s00296-016-3621-1 Finzel, 2013, Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors, Ann Rheum Dis, 72, 1176, 10.1136/annrheumdis-2012-201580 Kavanaugh, 2012, Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial, Arthritis Rheum, 64, 2504, 10.1002/art.34436 Behrens, 2016, Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a large observational Study, J Rheumatol, 43, 632, 10.3899/jrheum.141596 Haibel, 2010, Use of methotrexate in patients with ankylosing spondylitis, Clin Exp Rheumatol, 28, S128 Dobner, 2013, A three-centre experience with adalimumab for the treatment of non-infectious uveitis, Br J Ophthalmol, 97, 134, 10.1136/bjophthalmol-2011-301401 Gladman, 2007, Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial, Arthritis Rheum, 56, 476, 10.1002/art.22379 Kavanaugh, 1689, Clinical efficacy, radiographic and safety findings through 5? Years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study), Ann Rheum Dis, 2014, 94 Van der Heijde, 2007, Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2, Arthritis Rheum, 56, 2698, 10.1002/art.22805 Fraser, 2005, A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis, Ann Rheum Dis, 64, 859, 10.1136/ard.2004.024463 Sakellariou, 2013, Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate, Rheumatol Int, 33, 2917, 10.1007/s00296-012-2534-x Ritchlin, 2014, Ann Rheum Dis, 73, 990, 10.1136/annrheumdis-2013-204655 Sterry, 2010, Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial, BMJ, 340, c147, 10.1136/bmj.c147 Kristensen, 2008, Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group register, Ann Rheum Dis, 67, 364, 10.1136/ard.2007.073544 Glintborg, 2011, Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: Results from the nationwide Danish DANBIO registry, Arthritis Rheum, 63, 382, 10.1002/art.30117 Heiberg, 2008, The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study, Arthritis Rheum, 59, 234, 10.1002/art.23333 Grismer, 2001, Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity, J Clin Rheumatol, 7, 224, 10.1097/00124743-200108000-00007 Haustein, 2000, Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment, J Eur Acad Dermatol Venereol, 14, 382, 10.1046/j.1468-3083.2000.00058.x